Notes
In the study, additional paclitaxel on day 8 for the initial 2 or 3 cycles was given to patients with emerging disease [ it is unclear whether this patient received additional paclitaxel].
Reference
Kunieda K, et al. Bevacizumab plus paclitaxel for HER2 negative advanced/recurrent breast cancer: Assessment of efficacy and safety. Annals of Oncology 25 (Suppl. 5): v75-v109, Oct 2014. Available from: URL: http://annonc.oxfordjournals.org/content/25/suppl_5/v75.5.abstract?sid=e82b95d7-60d5-4e7b-a071-28dc66bc9b1a [abstract] - Japan
Rights and permissions
About this article
Cite this article
Bevacizumab/paclitaxel. Reactions Weekly 1542, 49 (2015). https://doi.org/10.1007/s40278-015-8457-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-015-8457-z